睿知中国医院研究地图
候选清单

正在招募肺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer

ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心同济大学附属东方医院Shanghai East Hospital, Tongji University上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07309276,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Have received any investigational drug within 4 weeks or 5 half-lives before the first use of the study drug;

    排除标准第 19 条

    Have received local small-scale radiotherapy within 14 days;

    排除标准第 22 条

  3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.

    入选标准第 5 条

  4. According to the Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1), there must be at least one measurable lesion.

    入选标准第 4 条

  5. Tumor histological or cytological pathological confirmation of combined large cell neuroendocrine carcinoma or sarcomatoid lesion, or NSCLC with small cell lung cancer component;

    排除标准第 2 条

    Participants who were diagnosed with any other malignant tumor within 5 years.

    排除标准第 26 条

  6. Female participants with reproductive capacity (WOCBP) who have sexual life with an unsterilized male partner and who have signed the informed consent must have a negative serum pregnancy test result within 7 days before the first administration, and must agree to take effective contraceptive measures from the time of signing the ICF until 7 months after the last administration of the study.

    入选标准第 8 条

    Unsterilized male participants who have sexual life with a fertile female partner must agree to use the effective contraceptive measures after signing the ICF until 4 months after the last administration of the study. During this period, sperm donation is prohibited.

    入选标准第 9 条

    Female participants who are pregnant, breastfeeding, or planning to become pregnant during the study period.

    排除标准第 27 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07309276,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. The age between 18 and 75 years old, and any gender.
  2. Local advanced, metastatic or recurrent NSCLC.
  3. ES-SCLC.
  4. According to the Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1), there must be at least one measurable lesion.
  5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
  6. Expected survival period of ≥ 12 weeks.
  7. The functions of important organs meet the requirements.
  8. Female participants with reproductive capacity (WOCBP) who have sexual life with an unsterilized male partner and who have signed the informed consent must have a negative serum pregnancy test result within 7 days before the first administration, and must agree to take effective contraceptive measures from the time of signing the ICF until 7 months after the last administration of the study.
  9. Unsterilized male participants who have sexual life with a fertile female partner must agree to use the effective contraceptive measures after signing the ICF until 4 months after the last administration of the study. During this period, sperm donation is prohibited.
  10. The participants voluntarily participate in this study and sign the informed consent.

排除标准:Exclusion Criteria:

  1. Accompanying the following disease states:
  2. Tumor histological or cytological pathological confirmation of combined large cell neuroendocrine carcinoma or sarcomatoid lesion, or NSCLC with small cell lung cancer component;
  3. NSCLC patients with positive driver mutations;
  4. Patients with known meningeal metastasis;
  5. Patients with symptomatic brain metastases;
  6. Uncontrolled pleural effusion, pericardial effusion, or recurrent ascites;
  7. Unatable spinal cord compression;
  8. Participants in Cohort 1 and Cohort 4 need to exclude any of the following conditions:
  9. Within one month before the first use of the study drug, any clinically significant hemoptysis or tumor bleeding;
  10. High bleeding risk; tumor invading important organs, high risks of perforation, esophageal-tracheal fistula, massive hemoptysis, etc.;
  11. Obvious bleeding tendency or severe coagulation dysfunction history, etc;
  12. Recent gastrointestinal perforation, gastrointestinal obstruction, trachea-esophageal fistula, abdominal fistula or intra-abdominal abscess, or currently having high-risk factors for hollow organ perforation/ fistula formation, or active inflammatory bowel disease, etc;
  13. Presence of severe, non-healed or open wounds, active ulcers or untreated fractures;
  14. Have poorly controlled hypertension;
  15. Have used antiplatelet drugs or anticoagulant therapy within 14 days;
  16. Have experienced a drug-related adverse event that led to permanent discontinuation of the medication during previous Bevacizumab and similar agent treatments;
  17. Have received any of the following treatments:
  18. Immune-mediated treatments (only for part Two);
  19. Have received any investigational drug within 4 weeks or 5 half-lives before the first use of the study drug;
  20. Have been enrolled in another clinical study;
  21. Have undergone major surgery within 4 weeks;
  22. Have received local small-scale radiotherapy within 14 days;
  23. Long QT;
  24. Left ventricular ejection fraction (LVEF) < 50%;
  25. Uncontrolled concurrent diseases.
  26. Participants who were diagnosed with any other malignant tumor within 5 years.
  27. Female participants who are pregnant, breastfeeding, or planning to become pregnant during the study period.
  28. Other conditions for trial participation were not considered appropriate by the investigator.

引自 ClinicalTrials.gov, NCT07309276, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07309276,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07309276